Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The objective of the present study was to investigate the applicability of a new human growth hormone (Zomacton) formulation, administered both by a conventional syringe and by a new needle-free device (ZomaJet 2 Vision).

Why It Was Studied

The study was performed according to a randomized, controlled, three-period crossover design.

No subjects were withdrawn due to adverse events.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, men only.

How the Study Was Run

The design is described as randomized and crossover.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

Bioequivalence was assessed based on log-transformed AUC and C(max) values.

What Was Measured

PubMed files the paper under topics including Area Under Curve, Biological Availability, Half-Life, Human Growth Hormone, Injections, Jet and Syringes.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2002 (Journal of clinical pharmacology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.